{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T01:07:44Z","timestamp":1788052064412,"version":"build-2784847793"},"reference-count":9,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Genetics and Cytogenetics"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1016\/j.cancergencyto.2010.05.012","type":"journal-article","created":{"date-parts":[[2010,8,3]],"date-time":"2010-08-03T10:14:18Z","timestamp":1280830458000},"page":"133-134","source":"Crossref","is-referenced-by-count":12,"title":["Chronic myeloid leukemia with e19a2 atypical transcript: early imatinib resistance and complete response to dasatinib"],"prefix":"10.1016","volume":"201","author":[{"given":"S. Eric","family":"Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Sausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brewster F.","family":"Kingham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cancergencyto.2010.05.012_bib1","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","article-title":"Molecular biology of bcr-abl1-positive chronic myeloid leukemia","volume":"113","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.cancergencyto.2010.05.012_bib2","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1182\/blood.V76.9.1819.1819","article-title":"New type of Bcr\/Abl junction in Philadelphia chromosome-positive chronic myelogenous leukemia","volume":"76","author":"Saglio","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.cancergencyto.2010.05.012_bib3","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.leukres.2007.08.017","article-title":"A multiplex PCR for improved detection of typical and atypical BCR-ABL fusion transcripts","volume":"32","author":"Burmeister","year":"2008","journal-title":"Leuk Res"},{"key":"10.1016\/j.cancergencyto.2010.05.012_bib4","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1002\/cncr.10490","article-title":"Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR\/ABL mRNA and undetectable BCR\/ABL protein may predict an indolent course","volume":"94","author":"Verstovsek","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.cancergencyto.2010.05.012_bib5","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1038\/sj.leu.2403454","article-title":"Imatinib induces a cytogenetic response in blast crisis or interferon failure chronic myeloid leukemia patients with e19a2 BCR-ABL transcripts","volume":"18","author":"Lee","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.cancergencyto.2010.05.012_bib6","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.leukres.2007.03.001","article-title":"Y253H mutation appearing in a micro-BCR-ABL (e19a2) CML","volume":"32","author":"Popovici","year":"2008","journal-title":"Leuk Res"},{"key":"10.1016\/j.cancergencyto.2010.05.012_bib7","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2009-04-214221","article-title":"Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations","volume":"114","author":"M\u00fcller","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.cancergencyto.2010.05.012_bib8","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/leu.2008.3","article-title":"BCR-ABL mutants spread resistance to non-mutated cells through a paracrine mechanism","volume":"22","author":"Liu","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.cancergencyto.2010.05.012_bib9","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"}],"container-title":["Cancer Genetics and Cytogenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016546081000227X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016546081000227X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T22:49:23Z","timestamp":1591742963000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016546081000227X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":9,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["S016546081000227X"],"URL":"https:\/\/doi.org\/10.1016\/j.cancergencyto.2010.05.012","relation":{},"ISSN":["0165-4608"],"issn-type":[{"value":"0165-4608","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}